Anglo-Swedish pharmaceuticals giant AstraZeneca on Tuesday agreed to buy US biopharma firm Fusion for up to $2.4 billion
PHOTO
Anglo-Swedish pharmaceuticals giant AstraZeneca on Tuesday agreed to buy US biopharma firm Fusion for up to $2.4 billion, in the group's latest expansion into cancer treatments.
"The acquisition marks a major step forward in AstraZeneca delivering on its ambition to transform cancer treatment and outcomes for patients by replacing traditional regimens like chemotherapy and radiotherapy with more targeted treatments," the company said in a statement.
Disclaimer: The content of this article is syndicated or provided to this website from an external third party provider. We are not responsible for, and do not control, such external websites, entities, applications or media publishers. The body of the text is provided on an “as is” and “as available” basis and has not been edited in any way. Neither we nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this article. Read our full disclaimer policy here.
